Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study

Table 2 Association of amyloid-β levels with neurodegenerative markers

Plasma Aβ levels (per SD decrease)	Total brain volume, mean difference (95% CI),^a p value	Total gray matter volume, mean difference (95% CI),^a p value	Total white matter volume, mean difference (95% CI),^a p value	Total hippocampal volume, mean difference (95% CI),^a p value
Aβ_1–38	0.03 (− 0.03; 0.08), p = 0.362	0.02 (− 0.10; 0.15), p = 0.715	0.01 (− 0.09; 0.12), p = 0.819	0.04 (− 0.11; 0.19), p = 0.582
Aβ_1–40	− 0.04 (− 0.09; 0.02), p = 0.171	− 0.08 (− 0.21; 0.06), p = 0.248	0.01 (− 0.11; 0.12), p = 0.912	− 0.01 (− 0.17; 0.14), p = 0.869
Aβ_1–42	0.00 (− 0.03; 0.04), p = 0.812	− 0.06 (− 0.14; 0.03), p = 0.174	0.04 (− 0.03; 0.12), p = 0.251	− 0.13 (− 0.23; − 0.04), p = 0.007
Aβ_1–40/Aβ_1–42 ratio	0.03 (− 0.02; 0.09) p = 0.231	0.06 (− 0.07; 0.19), p = 0.380	−0.00 (− 0.11; 0.11) p = 0.998	−0.10 (− 0.25; 0.05), p = 0.194

Abbreviations: Aβ amyloid-β, SD standard deviation, CI confidence interval
^a Adjusted for age, sex, mean arterial blood pressure, total cholesterol, diabetes, apolipoprotein ε4 carrier status, smoking, intracranial volume and other Aβ levels

ISSN: 1758-9193